Bright spot was a slight rise in Protagonist shares on polycythemia vera results

BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5

Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra

Agency reassessing breakthrough designation for polycythemia vera after adverse events

After signaling that an ex-U.S. deal was in the works, Sierra chose the M&A route, giving GSK global rights to a late-stage myelofibrosis candidate

Plus new CMO at Avenge Bio, new CEO at 

Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance

Biocon partners with Serum Institute, plus Santé’s $260M fund, IASO Bio’s $108M series C, Everest in $12M renal deal and more

Keros will look to fund ongoing clinical work via a listing that builds on this month’s series C round